Back to results
US 2025/0025582 A1Published application
Ligands and their use
AssigneeThe University of Sydney
InventorsRachel CODD, James Liam WOOD, Christopher John McCormack BROWN
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compounds that include a first chelating ligand selective for 89Zr linked by a linker group to a second chelating ligand selective for a radionuclide other than 89Zr. Also disclosed are complexes, pharmaceutical agents and compositions comprising the compounds. The disclosure also provides methods for the use and production of the compounds, complexes, pharmaceutical agents and compositions.
Claims26
A compound comprising:
- a first chelating ligand selective for 89Zr, and
- a second chelating ligand selective for a nuclide of pharmaceutical potential other than 89Zr,
- wherein the first and second chelating ligands are covalently linked by a linker group.
(canceled)
(canceled)
(canceled)
A compound of formula (II)
- Ch1-L-Ch2 (II)
- wherein
- Ch1 is a radical of desferrioxamine B;
- Ch2 is a radical selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), alpha-(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTAGA) or 7-[2-[bis(carboxymethyl)amino]ethyl]hexahydro-1H-1,4,7-triazonine-1,4(5H)-diacetic acid (NETA);
- and
- L is a linker group.
3 more elements
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.